MilliporeSigma's Viral Vector CDMO has developed a high-performing, scalable

manufacturing platform for AAV gene therapy production across multiple serotypes. The
platform integrates an optimized transient cell line and expression media for upstream
processing, combined with a robust downstream workflow including clarification, two-
step purification, TFF, and final filtration. Demonstrated successfully from 3 L bench
scale to 1000 L scale, the platform delivers consistent genomic titers, full capsid quality,
and effective impurity removal, offering a streamlined, end-to-end solution to accelerate
gene therapy development, making it well-suited for clinical and commercial AAV
production.